PE Firm Carlyle Group is in talks to purchase Albany Molecular
Albany Molecular $AMRI is a contract research and manufacturing company
Albany Molecular Research $AMRI is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments.
Reuters reports that private equity firms GTCR LLC and Carlyle Group LP $CG are in talks to team up and jointly acquire Albany Molecular. Negotiations are ongoing, and there is no certainty that the talks will lead to Albany Molecular Research being taken private, the report said.
Drug manufacturers are under pressure to lower drug costs and that has created M&A activities in the sector. Other stocks in the sector that might be looked as potential take over targets include: #Cambrex Corporation $CBM , Charles River Labs. $CRL , Emergent Biosolutions $EBS . TESARO $TSRO , the oncology-focused biopharmaceutical company, recently announced that it is shopping itself.
AMRI last traded at $19.91.
The Carlyle Group L.P. $CG is a diversified multi-product global alternative asset management firm. The Company operates in four segments: Corporate Private Equity (CPE), Real Assets, Global Market Strategies (GMS) and Investment Solutions. Corporate Private Equity advises its buyout and growth capital funds, which pursue various corporate investments of different sizes and growth potentials.
The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.